By Fineline Cube China-based Harbour BioMed (HKG: 2142) has announced receiving clinical trial approval from the US FDA for its bispecific antibody HBM7008. The drug, which targets the tumor antigen B7H4 and T cell co-stimulatory molecule 4-1BB, was first dosed in Phase I clinical trials in Australia in May and obtained clinical approval in China in June this year.
Mechanism and Targeting
HBM7008 is designed to specifically activate T cells only when binding to B7H4, thereby exerting an anti-tumor effect with improved safety. B7H4 is overexpressed in various malignant solid tumors, including breast, non-small cell lung, ovarian, and endometrial cancers. This targeted approach positions HBM7008 as a promising candidate for patients who are PD-L1-negative or resistant to PD-1/PD-L1 immunotherapy drugs.-Fineline Info & Tech